ANZ Group (ASX:ANZ) has seen a rise as analysts at Morgan Stanley have raised their price target on the Australian corporation from A$26.20 to A$27 per share.

Moving from equal-weight to over-weight, Morgan Stanley has also upgraded their stock rating of ANZ Group (ASX:ANZ).

The shares of ANZ Group (ASX:ANZ) were up by 1.7% at A$25.63.

The organization appears to be having an exceptional day, since it is the sole gainer amongst the ‘Big Four’ lenders.

ANZ Group (ASX:ANZ) continues to be Morgan Stanley’s preferred major bank in Australia.

A highlight in its favor has been a mix of its business, improved operating performance, and valuation support.

Morgan Stanley contends that ANZ Group (ASX:ANZ) is ideally positioned to manage costs, catalyzed by its sound record of handling cost control.

Out of 14 analysts, nine rate the ANZ Group (ASX:ANZ) stock as ‘buy’ or higher, three maintain a ‘hold’ and two advise a ‘sell’.

Hence, their median price target is at A$26.13, according to LSEG data.

To note, ANZ Group’s stock has seen a rise of 6.5% this year, till the last closing.

ANZ Group (ASX:ANZ) is one of Australia’s largest banking groups.

Cokal (ASX:CKA) shares have seen a significant increase of 19.1%, reaching A$0.125.

This marks the company’s best day since October 2021, if the gains maintain this momentum.

The influence behind this growth appears to be the jetty operations permit that the coal company has received.

This permit is for operations associated with the Bumi Barito Mineral (BBM) metallurgical coal mine located in Indonesia.

With this permit, Cokal is moving forward with the scheduling of its maiden shipment of BBM coal at the earliest possible time.

Approximately 2.2 million shares have already changed hands, surpassing the last 30-day average volume of 754,854.

This development has brought the Cokal stock to its highest level since August 29.

Although the day’s gains still mark an overall loss of around 42% on the year, this indicates a favorable turning point.

Cokal is a coal mining company that operates primarily in Indonesia.

Analysts at UBS view the bond issue by Mineral Resources (ASX:MIN) as an approach to de-risk capital expenditure during a period of intense construction activity.

The Australian lithium miner declared on Tuesday, plans to offer up to $850 million of senior unsecured notes, without divulging further details.

UBS indicates that an increased balance sheet involvement for the company will naturally increase its exposure to weaker commodity prices.

The brokerage maintains a ‘sell’ rating on the company, with a price target.

Mineral Resources' shares saw a rise of 2.1% at A$67.63.

Out of 16 analysts, 10 rate the stock ‘buy’ or higher, three give a ‘hold’ and the remaining three rate ‘sell’ or lower.

The median price target is A$77.90, according to LSEG data.

This year, the stock has seen a decrease of 14.5%, as of the most recent closing.

Mineral Resources is an Australian lithium mining company.

Analysts at finance firm Macquarie have cut the price target on Fletcher Building, a major New Zealand company, from NZ$7.20 to NZ$6.70 per share.

This reduction is due to lower margin expectations from its Australia and New Zealand business, along with increased cost estimates for silicosis.

Despite this, Fletcher Building shares increased by 1.1% to NZ$4.65.

Macquarie predicts that constraints on ANZ’s construction markets will continue to impact the company.

It also reduces EPS estimates by 2% for FY24 and 3% for both FY25 and FY26.

Out of ten analysts, seven rate the stock as a “buy” or higher, two hold and one sells.

The median price target given is A$6.0, according to LSEG data.

Despite recent gains, Fletcher Building’s stock has fallen 2.5% this year, based on the last closing figures.

Fletcher Building (ASX:FBU) is a major construction company based in New Zealand, with prominent operations in both Australia and New Zealand.

Shares of Mach7 Technologies (ASX:M7T) are up by 8.5% at A$0.77, poised for their best day since July 13 if the gains continue.

The medical equipment company has signed a five-year contract extension with the Hospital Authority of Hong Kong for support and maintenance.

Mach7 announces that the value of the contract extension is A$15.26 million, with a recurring revenue value of A$12.36 million.

Mach7’s stock is now at its highest level since Sept.

The stock has risen 24.5% YTD, as of last close.

Mach7 Technologies (ASX:M7T) is a medical equipment company that specializes in support and maintenance services.

Shares in Alliance Nickel (ASX:AXN) rose by 7.9% to A$0.068 today, and could see their best day since September 7th if the gains hold.

This places the shares of this Australian mineral explorer at their highest level since September 21.

Alliance Nickel (ASX:AXN) announced that it has received the tranche 2 funds of A$2.3 million from a strategic placement to Stellantis N.V.

This placement now means that Stellantis N.V holds an 11.5% shareholding in Alliance Nickel (ASX:AXN) and has also acquired the right to nominate one director to the company’s board.

Approximately 704,370 shares exchanged hands, a significant increase compared to the 30-day average volume of 234,680.

Including today’s gains, the stock is down 30.7% overall for this year.

Alliance Nickel is an Australian-based mineral exploration company.

Noxopharm (ASX:NOX) shares have seen an increase of as much as 10.5% to A$0.042, marking their highest level since August 1.

This rise comes on the heels of promising test results in the field of biotechnology for the novel dual-cell CRO-67 preclinical drug candidate.

The drug has shown a significant reduction in tumour volume and slower growth.

Currently, Noxopharm is developing CRO-67 as a potential treatment for pancreatic cancer, which has led to its biggest intraday jump since August 1.

However, the shares of Noxopharm have been down by 73.8% year-to-date as of the last close.

Noxopharm is an Australian drug development company focusing on the commercialization of its drug to improve the effectiveness and safety of chemotherapy and radiotherapy.

Shares of Australian company Santos (ASX:STO) saw a major surge of as much as 3.7% to A$7.94.

If the gains are maintained, it would make it Santos' best day since mid-June.

The shares of the oil and gas behemoth have been positively reviewed by analysts at UBS, who raised their price target for Santos from A$8.70/share to A$8.80/share, maintaining the ‘Buy’ rating for the company.

UBS has expressed an ‘incremental’ positive outlook for the team at Santos' Pikka Project in Alaska and believes that Santos is determined to sell down a 15% stake in the project over the course of the following year.

They have also increased their EPS expectations for 2023-2025 by 4-8% to reflect the 2.6% sell-down of the company’s stake in the PNG LNG Project.

LSEG data also shows that 12 out of 15 analysts rate the stock ‘buy’ or higher, and three rate it ‘hold,’ with a median price target of A$8.88.

So far, this year as of last close, Santos' stock has risen by 7.3%.

Santos is a major Australian oil and gas company.

Zenith Minerals shares had a significant surge, rising as much as 4.4% to A$0.095.

This is being eyed as their best performance since September 11 if the gains hold.

The precious metals explorer carried out its inaugural mineral resource estimate for the Rio Lithium Deposit, part of the company’s Split Rocks project located in Western Australia.

Notably, the company identified notable lithium grades from the resource estimate.

Zenith Minerals noted that additional drilling is needed to determine the full scope of lithium mineralization at the site.

In recent trading, Zenith’s shares reached their highest point since September 21.

Despite this, the company’s shares are down by approximately 66% for this year based on the latest recorded close.

A 20-word company description: Zenith Minerals is a mining company engaged in the exploration and development of precious and base metals in Australia.

Allkem (ASX:AKE) shares rise as much as 4.37% to A$11.815 as the $10.6 billion merger with U.S.-based Livent nears completion.

The lithium miner announced it has received, or will soon receive, required completion and foreign investment approvals for its planned merger.

This development brings about the largest intraday percentage gain in the stock since August 22.

Analysts' average rating mirrors a strong ‘Buy’, with their median price target set at A$16.5.

The recent rush had about 1.6 million shares changing hands, compared to the 30-day average volume of 2.8 million shares.

Despite the metals and mining index experiencing a 5.17% decline this year, Allkem’s stock has risen 0.71% as of the last closing.

Allkem is a resource company focusing primarily on lithium mining.